The system will be going down for regular maintenance. Please save your work and logout.
Evaluating the Use of Generalized Dynamic Weighted Ordinary Least Squares for Individualized Hiv Treatment Strategies
VILLAIN, Laura
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
See more >
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
VILLAIN, Laura
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
THIEBAUT, Rodolphe
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
< Reduce
Statistics In System biology and Translational Medicine [SISTM]
Bordeaux population health [BPH]
Language
EN
Article de revue
This item was published in
Annals of Applied Statistics. 2023-09, vol. 17, n° 3, p. 2432-2451
English Abstract
A dynamic treatment regimes (DTR) represents a statistical paradigm in precision medicine which aims to optimize patient outcomes by individualizing treatments. At its simplest, a DTR may require only a single decision to ...Read more >
A dynamic treatment regimes (DTR) represents a statistical paradigm in precision medicine which aims to optimize patient outcomes by individualizing treatments. At its simplest, a DTR may require only a single decision to be made; this special case is called an individualized treatment rule (ITR) and is often used to maximize short-term rewards. Generalized dynamic weighted ordinary least squares (G-dWOLS), a DTR estimation method that offers theoretical advantages such as double robustness of parameter estimators in the decision rules, has been recently extended to accommodate categorical treatments. In this work G-dWOLS is applied to longitudinal data to estimate an optimal ITR. This novel method is demonstrated in simulations and is then applied to a population affected by HIV, whereby an ITR for the administration of Interleukin 7 (IL-7) is devised to maximize the duration where the CD4 load is above a healthy threshold (500 cells/mu L) while preventing the administration of unnecessary injections.Read less <
